Citius Pharmaceuticals, Inc. (CTXR) Total liabilities 2017–2022
Citius Pharmaceuticals, Inc. (CTXR) total liabilities at each fiscal year-end, per SEC filings.
$10.6MFY2022 · since FY2017: $2.5M → $10.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2022 | $10.6M | +9.6% |
| FY2021 | $9.6M | -4.5% |
| FY2020 | $10.1M | +5.3% |
| FY2019 | $9.6M | +2236.2% |
| FY2018 | $410,640 | -83.4% |
| FY2017 | $2.5M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More CTXR financial trends
CTXR RevenueCTXR Net incomeCTXR Net marginCTXR Gross profitCTXR Gross marginCTXR Operating incomeCTXR Operating marginCTXR Operating cash flowCTXR Free cash flowCTXR Capital expendituresCTXR Return on equityCTXR Stock buybacksCTXR Dividends paidCTXR Total assetsCTXR Shareholders’ equityCTXR overview →